Myeloid Transforming Protein Evi1 Interacts with Methyl-CpG Binding Domain Protein 3 and Inhibits in Vitro Histone Deacetylation by Mbd3/Mi-2/NuRD
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The ecotropic viral integration site 1 ( Evi1) gene encodes a putative transcription regulator, which is aberrantly expressed in acute myeloid leukemias (AML) with chromosomal abnormalities involving the 3q26 locus. Repression and activation of transcriptional control have been reported, but it is currently unclear how Evi1 may evoke these opposing effects. Using a yeast two-hybrid screen, we identified a novel binding partner of Evi1, i.e., methyl binding domain 3b (Mbd3b) protein, a member of the Mi-2/NuRD histone deacetylase complex. Applying in vitro and in vivo assays, we found that Evi1 interacts with Mbd3b but not with other MBD family members Mbd1, -2, and -4 or MeCP2. We show that interaction of Evi1 with Mbd3 requires 40 amino acids that are adjacent and downstream of the methyl binding domain (MBD). We further demonstrate that the first three zinc fingers of Evi1 are needed for Mbd3 interaction. Evi1 acts as a transcriptional repressor when recruited to an active promoter, yet when present in the Mi-2/NuRD complex through Mbd3 interaction, it inhibits the histone deacetylation function of this multiprotein structure. Our data may in part explain how Evi1 could act as a repressor as well as an activator of transcription.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103
MBD2/NuRD and MBD3/NuRD, Two Distinct Complexes with Different Biochemical and Functional Properties
Le Guezennec, X., Vermeulen, M., Brinkman, A. B., Hoeijmakers, W. A. M., Cohen, A., Lasonder, E., & Stunnenberg, H. G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.843-851.2006 · Cited by 340
Self-citationAn Ikaros-Containing Chromatin-Remodeling Complex in Adult-Type Erythroid Cells
O'Neill, D. W., Schoetz, S. S., Lopez, R. A., Castle, M., Rabinowitz, L., Shor, E., Krawchuk, D., Goll, M. G., Renz, M., Seelig, H.-P., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7572-7582.2000 · Cited by 160
Cited by
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia
Wouters, B. J., & Delwel, R. (2016) · Blood · doi:10.1182/blood-2015-07-604512 · Cited by 292
Self-citationThe prdm family: expanding roles in stem cells and development
Hohenauer, T., & Moore, A. W. (2012) · Development · doi:10.1242/dev.070110 · Cited by 265
“Here, we discuss some of these recent studies, which REVIEW Development 139 (13) Factor Intrinsic enzymatic activity Binding to chromatin modifiers Other co-repressors and binding partners Prdm1 G9a (Gyory et al., 2004), Lsd1 (Su et al., 2009), Hdac2 (Yu et al., 2000), Prmt5 (Ancelin et al., 2006) Groucho family (Tle1…”
InfluentialPRDM proteins: important players in differentiation and disease
Fog, C. K., Galli, G. G., & Lund, A. H. (2012) · BioEssays · doi:10.1002/bies.201100107 · Cited by 201
“PRDMs’ molecular mechanisms in transcriptional regulation Name Common alias HMT activity (in complex) Consensus sequence Binding partners PRDM1 BLIMP1 (Prmt5 H2AR3me2s, H4R3me2s [14]), (G9a H3K9me2 [9]) Yes [99] G9a [9], HDAC2 [13], IRF4 [100], LSD1 [15], PRMT5 [14], TLE1, TLE2 [18] PRDM2 RIZ1/2 H3K9me2 [6] ER [101],…”
Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2
Pastoors, D., Havermans, M., Mulet-Lazaro, R., Brian, D., Noort, W., Grasel, J., Hoogenboezem, R., Smeenk, L., Demmers, J. A. A., Milsom, M. D., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk9076 · Cited by 15
Self-citation
Metadata
- Authors
- Spensberger, D., Vermeulen, M., Le Guezennec, X., Beekman, R., van Hoven, A., Bindels, E., Stunnenberg, H., & Delwel, R.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-05-24
- Volume
- 47
- Issue
- 24
- Pages
- 6418-6426
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2168705614
- Cited by
- 22
- References
- 3
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myeloid Transforming Protein Evi1 Interacts with Methyl-CpG Binding Domain Protein 3 and Inhibits in Vitro Histone Deacetylation by Mbd3/Mi-2/NuRD. https://app.cochat.ai/papers/10.1021/bi800267f
- The paper
- Spensberger, D., Vermeulen, M., Le Guezennec, X., Beekman, R., van Hoven, A., Bindels, E., Stunnenberg, H., & Delwel, R. (2008). Myeloid Transforming Protein Evi1 Interacts with Methyl-CpG Binding Domain Protein 3 and Inhibits in Vitro Histone Deacetylation by Mbd3/Mi-2/NuRD. Biochemistry. https://doi.org/10.1021/bi800267f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.